Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
$0.00
$0.00
$0.16
$73K-0.0760,924 shsN/A
NEPTF
Neptune Wellness Solutions
$0.01
$0.02
$0.00
$0.12
$63K-3.133,683 shs1 shs
OREXQ
Orexigen Therapeutics
$0.01
+35.9%
$0.01
$0.00
$0.16
$100K4.9880,439 shs60,300 shs
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
$0.00
$0.00
$0.04
$32K-0.7762,884 shsN/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
0.00%0.00%0.00%0.00%+200.00%
NEPTF
Neptune Wellness Solutions
0.00%0.00%+180.00%-53.33%+1,399,900.00%
OREXQ
Orexigen Therapeutics
0.00%0.00%0.00%0.00%0.00%
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
0.0115 of 5 stars
0.01.00.00.00.60.00.0
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
0.00
N/AN/AN/A
NEPTF
Neptune Wellness Solutions
2.00
HoldN/AN/A
OREXQ
Orexigen Therapeutics
0.00
N/AN/AN/A
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
$2.66M0.00N/AN/AN/ANaN
NEPTF
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
OREXQ
Orexigen Therapeutics
$33.71M0.00N/AN/AN/A
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
-$33.33MN/A0.00N/AN/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
-$24.52MN/A0.00N/AN/AN/AN/AN/A
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/AN/AN/A
NEPTF
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
OREXQ
Orexigen Therapeutics
N/AN/AN/AN/AN/A
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/AN/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
15122.06 million79.09 millionNot Optionable
NEPTF
Neptune Wellness Solutions
1304.53 million4.30 millionN/A
OREXQ
Orexigen Therapeutics
13218.89 millionN/ANot Optionable
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
62316.67 millionN/ANot Optionable

Recent News About These Companies

Tech group eyes AI standards
Predictive Technology Group Inc
Predictive Technology Group Inc (PRED)
Most orgs still don’t have generative AI policies. Why?
Ascension Enhances Broadband Deployment with Render Technology

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Generex Biotechnology stock logo

Generex Biotechnology OTCMKTS:GNBT

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

Neptune Wellness Solutions OTC:NEPTF

$0.01 0.00 (0.00%)
As of 07/3/2025

Neptune Wellness Solutions Inc. operates as an integrated health and wellness company. It builds a portfolio of lifestyle brands and consumer packaged goods products under the Biodroga Neutraceuticals, Forest Remedies, Ocean Remedies, Neptune Wellness, Mood Ring, PanHash, Sprout, Nosh, and NurturMe brands. The company offers turnkey product development and supply chain solutions to business customers in various health and wellness verticals, such as legal cannabis and hemp, nutraceuticals, and white label consumer packaged goods. It is also involved in the extraction, purification, formulation, and manufacturing of health and wellness products, such as omega-3 and hemp-derived products under various delivery forms, such as soft gels, liquids, capsules, vape pens, sprays, topicals, sachets, tinctures, concentrates, edibles, and beverages, as well as hand sanitizers, non-contact thermometers, and gloves. In addition, the company offers Maxsimil, an omega-3 fatty acid delivery technology that uses enzymes that mimic the natural human digestive system to predigest omega-3 fatty acids. It has a collaboration agreement with International Flavors & Fragrances Inc. to co-develop hemp-derived CBD products for the mass retail, and health and wellness markets. The company was incorporated in 1998 and is headquartered in Laval, Canada.

Orexigen Therapeutics OTCMKTS:OREXQ

$0.0053 +0.00 (+35.90%)
As of 05/31/2019

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Predictive Technology Group stock logo

Predictive Technology Group OTCMKTS:PRED

Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah. On November 9, 2023, Predictive Technology Group, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Utah. On January 12, 2024, the voluntary petition of Predictive Technology Group, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on November 9, 2023.